Multiple systemic embolism in infective endocarditis underlying in Barlow’s disease

Ziqing Yu¹,²†, Bing Fan¹†, Hongyi Wu¹, Xiangfei Wang¹, Chenguang Li¹, Rende Xu¹, Yangang Su²* and Junbo Ge¹*

Abstract

Background: Systemic embolism, especially septic embolism, is a severe complication of infective endocarditis (IE). However, concurrent embolism to the brain, coronary arteries, and spleen is very rare. Because of the risk of hemorrhage or visceral rupture, anticoagulants are recommended only if an indication is present, e.g. prosthetic valve. Antiplatelet therapy in IE is controversial, but theoretically, this therapy has the potential to prevent and treat thrombosis and embolism in IE. Unfortunately, clinical trial results have been inconclusive.

Case presentation: We describe a previously healthy 50-year-old man who presented with dysarthria secondary to bacterial endocarditis with multiple cerebral, coronary, splenic, and peripheral emboli; antibiotic therapy contributed to the multiple emboli. Emergency splenectomy was performed, with subsequent mitral valve repair. Pathological examination confirmed mucoid degeneration and mitral valve prolapse (Barlow’s disease) as the underlying etiology of the endocardial lesion. Continuous antibiotics were prescribed, postoperatively. Transthoracic echocardiography at 1.5, 3, and 6 months after the onset of his illness showed no severe regurgitation, and there was no respiratory distress, fever, or lethargy during follow-up.

Conclusions: Although antibiotic use in IE carries a risk of septic embolism, these drugs have bactericidal and antithrombotic benefits. It is important to consider that negative blood culture and symptom resolution do not confirm complete elimination of bacteria. However, vegetation size and Staphylococcus aureus infection accurately predict embolization. It is also important to consider that bacteria can be segregated from the microbicide when embedded in platelets and fibrin. Therefore, antimicrobial therapy with concurrent antiplatelet therapy should be considered carefully.

Keywords: Infective endocarditis, Embolism, Antiplatelet treatment
evidence of ischemia, and serum levels of troponin T, creatine kinase (CK), and CK-myoglobin (CK-MB) were normal; however, N-terminal-pro-brain natriuretic peptide (NT-pro-BNP) levels were increased (3277 pg/ml). The leukocyte count was 10620/mm$^3$, with neutrophils at 10 350/mm$^3$. The erythrocyte sediment rate was 68 mm/h, and blood culture was positive for group A $\beta$-hemolytic streptococcus. Transthoracic and transesophageal echocardiography revealed rupture of the mitral chordae tendineae, perforation of the leaflet, mitral vegetation measuring 40 × 30 mm, and severe regurgitation (Fig. 1b and Additional file 1). The left ventricular chamber was enlarged (left ventricular end-diastolic diameter: 64 mm; left ventricular end-systolic diameter: 45 mm), and the pulmonary artery was dilated (diameter: 33 mm; systolic pressure: 94 mm Hg). Cranial MRI revealed high signal intensity in the left hemisphere, indicating cerebral infarction (Fig. 1a). Abdominal ultrasound showed multiple echo-free areas in the spleen that suggested splenic abscess formation (Fig. 1c), and multiple blood cultures confirmed the presence of group A $\beta$-hemolytic Streptococcus. A diagnosis of left-sided native valve IE was made based on the modified Duke criteria, and the patient’s body temperature was well-controlled by ceftriaxone and vancomycin antibiotic therapy. However, 12 days after presentation, he complained of severe retrosternal chest pain radiating to his back, with ECG showing ST-segment elevation in V3, V4, and V5 leads (Fig. 2a), and increased troponin T (0.542 ng/ml) and CK-MB levels (25 u/l), confirming acute myocardial infarction (AMI). The mechanism of AMI secondary to IE is either compression by aortic periannular lesions or embolism [2]. Because his aorta was not involved, embolism was a concern. Repeat echocardiography showed left ventricular regional and segmental abnormal movement during contraction, supporting AMI. We elected not to initiate antiplatelet therapy, because of his cerebral infarction and splenic abscess, but valve surgery was planned. Unfortunately, 2 days later, he experienced acute-onset sharp abdominal pain with cold limbs, tenderness, muscle tension, guarding, hypotension, and tachycardia, suggesting peritonitis and shock. Bedside ultrasound revealed a 23-mm anechoic area in the abdominal cavity, and intraperitoneal hemorrhage was confirmed by abdominocentesis. Spontaneous splenic rupture was confirmed on emergency laparotomy. A necrotic area was seen in a section of the extracted spleen (Fig. 3a), and necrotic tissue with massive neutrophil and macrophage infiltration was observed microscopically, suggesting abscess formation secondary to
septic embolism (Fig. 3b). Mitral valvuloplasty was performed after the patient’s presentation, with vegetation resection, posterior valve repair, and flexible annuloplasty ring placement (Fig. 3c). Pathological analysis revealed mucoid degeneration of the mitral valve, inflammatory cell infiltration, and mural thrombus formation (Fig. 3d). We diagnosed mucoid degeneration and mitral valve prolapse (Barlow’s disease) as the underlying etiology of the endocardial lesion. Transthoracic echocardiography 1.5, 3, and 6 months after the onset of his illness showed no regurgitation, and there was no respiratory distress, fever, or lethargy during follow-up.

Conclusion
We described here an IE case with multiple systemic embolism in infective endocarditis underlying in Barlow’s disease. Although antibiotic use in IE carries a risk of septic embolism, these drugs have bactericidal and antithrombotic benefits. It is important to consider that negative blood culture and symptom resolution do not confirm complete elimination of bacteria. However, vegetation size and Staphylococcus aureus infection accurately predict embolization. It is also important to consider that bacteria can be segregated from the microbicide when embedded in platelets and fibrin. Therefore, antimicrobial therapy with concurrent antiplatelet therapy should be considered carefully.

Discussion
We report a unique IE case complicated by concurrent cerebral infarction, acute myocardial infarction, and splenic rupture. To our knowledge, a similar case has not been reported previously. In a retrospective study of IE, 499 of 1456 patients (34 %) were complicated by embolic events. Prosthetic valve location, right-sided endocarditis, Staphylococcus aureus infection, and vegetation size are considered high risk factors for embolism [3]. In prospective cohorts, embolic events occurred in 34.1 % [4], and 46 % [5] of patients, and age, sex, serum creatinine, and C-reactive protein levels were considered additional risk factors. In other studies [6], the incidence of embolism was 8.5 %, and a formula was developed to determine the likelihood of embolism, considering age, diabetes, atrial fibrillation, embolism before antibiotics, vegetation size, and Staphylococcus aureus infection. Results showed that vegetation size and Staphylococcus aureus infection validly predict embolization. In septic
embolism, antibiotics have dual effects including bactericidal and antithrombotic effects. However, systemic embolism tends to take place in patients with embolism before antibiotic treatment, increasing vegetation size in spite of antimicrobial therapy, when *Staphylococcus spp* are involved in the mitral valve vegetation [7]. Also, antibiotic regimes should be chosen carefully because different antibiotics have different effects on IE. One clinical study revealed that vancomycin and ampicillin were associated with significant reduction in vegetation size; however, cephalosporin and penicillinase-resistant drugs were associated with increased vegetation size and embolic risk [8]. Unfortunately, negative blood culture and resolution of clinical signs do not confirm bacterial elimination. One reason may be drug resistance, and another may be that antibiotics cannot access the center of the vegetation. The vegetation consists of platelets, fibrin, bacteria, and other components, and bacteria are segregated from endogenous microbicides such as some proteins, and exogenous antibiotics, by the platelets and fibrin. The outer crust of the vegetation envelops and confines the bacteria to prevent dissemination, but this protects bacteria from being thoroughly eliminated [9, 10]. It is not currently known which antibiotics perform better regarding anti-thrombosis; therefore, the best future antibiotics will have both good bactericidal effects, and good penetration into the vegetation. Currently, careful consideration should be given to whether concurrent antimicrobial therapy and antiplatelet therapy is more beneficial than antibiotics alone. In vitro, platelet aggregation can be antagonized by aspirin in the presence of bacteria isolated from blood culture [11]. In vivo animal experiments have shown that aspirin has antibacterial effects in IE, inhibiting bacterial adhesion to platelets and vegetation [12]. Aspirin has a dose-dependent effect on reducing vegetation size, with the greatest benefit at middle doses. This is perhaps because lower doses of aspirin do not completely inhibit platelets, while higher doses also decrease prostacyclin, which inhibits platelet aggregation. Regarding antiplatelet effects, aspirin and ticlopidine equally reduce vegetation.

Antiplatelet therapy can dramatically diminish vegetation, when used with vancomycin. However, clinical trials have shown contradictory effects of antiplatelet therapy. Some researchers argue that aspirin reduces stroke events, the number of patients requiring surgery, or mortality, without increasing hemorrhagic events [13–15]; however, these studies were
retrospective, and included small sample sizes. A prospective randomized controlled trial showed that aspirin failed to reduce the risk of embolism [16]. Because the cyclooxygenase pathway is not the only way to activate platelets, especially in endocarditis, the activator may not be derived from thromboxane A2; therefore, aspirin, which inhibits cyclooxygenase to reduce thromboxane A2, may play a less important role in IE. This theory may explain why aspirin performed poorly in a prospective trial, and thus, the need for more research regarding other antiplatelet drugs with mechanisms different from aspirin, such as clopidogrel, cilostazol, and ticagrelor, in preventing and treating embolism in IE. Considering the findings in current studies, antiplatelet therapy has potential in IE therapy.

Additional file

Additional file 1: Video Transesophageal echocardiogram during heart surgery (AVI 3.770 kb)

Abbreviations

AMI, acute myocardial infarction; CK, creatine kinase; IE, infective endocarditis; LVEDD, left ventricular end-diastolic dimension; LVEDS, left ventricular end-systolic dimension; NT-pro-BNP, N-Terminal-pro-Brain natriuretic peptide; TXA2, thromboxane A2

Acknowledgments

We would like to sincerely thank Heart Surgery Department of Zhongshan Hospital. Besides, the work was supported by grants from the Shanghai Municipal Commission of Health & Family Planning: Key Discipline (No. 12411952202) and Zhongshan hospital science fund (No. fund-044).

Funding

Shanghai Municipal Commission of Health & Family Planning: Key Discipline (No. 12411952202) and Zhongshan hospital science fund (No. fund-044).

Availability of data and materials

All data contained within this article.

Authors’ contributions

ZY participated in acquisition of data and drafting the initial and final manuscript; BF took part in clinical data acquisition and literature retrieval; XW, and HW took part in acquisition of clinical data; CL, and RX carried out acquisition of laboratory data; YS participated in acquisition data, having given final approval of the version to be published; JG wrote response letter to reviewer and gave final approval of the version to be published. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Written informed consent was obtained from the patient for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.

Author details

1Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai 200032, People's Republic of China. 2Shanghai Medical College, Fudan University, Shanghai 200032, People's Republic of China.

Received: 6 August 2015 Accepted: 20 July 2016
Published online: 11 August 2016

References

1. Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e5765–6005.
2. Manzano MC, Vilacosta I, San RJ, Aragoncillo P, Sarria C, Lopez D, et al. Acute coronary syndrome in infective endocarditis. Rev Esp Cardiol. 2007;60:24–31.
3. Rizzi M, Ravasio V, Carobbio A, et al. Predicting the occurrence of embolic events: an analysis of 1456 episodes of infective endocarditis from the Italian Study on Endocarditis (ISIE). BMC Infect Dis. 2014;14:230.
4. Thuny F, Di Salvo G, Belliard O, et al. Risk of embolism and death in infective endocarditis: prognostic value of echocardiography: a prospective multicenter study. J Am Coll Cardiol. 2005;112(1):69–75.
5. Durante ME, Adinolfi LE, Tripodi MF, et al. Risk factors for "major" embolic events in hospitalized patients with infective endocarditis. J Am Heart J. 2003;146(2):311–6.
6. Hubert S, Thuny F, Ressiguier N, et al. Prediction of symptomatic embolism in infective endocarditis: construction and validation of a risk calculator in a multicenter cohort. J Am Coll Cardiol. 2013;62(15):1384–92.
7. Vilacosta I, Graupner C, San RJ, et al. Risk of embolization after institution of antibiotic therapy for infective endocarditis. J Am Coll Cardiol. 2002;39(9):1489–95.
8. Rohmann S, Erhel R, Darius H, et al. Effect of antibiotic treatment on vegetation size and complication rate in infective endocarditis. J Clin Microbiol. 1997;35(2):132–40.
9. McColm AA, Ryan DM. Penetration of beta-lactam antibiotics into cardiac vegetations, aorta and heart muscle in experimental Staphylococcus aureus endocarditis: comparison of ceftazidime, cefuroxime and methicillin. J Antimicrob Chemother. 1985;16:349–58.
10. Eng RH, Parkin P, Tecson-Tumang F. Penetration of antibiotics into vegetation of heart valves: a mathematical model. Chemotherapy. 1982;28:421–7.
11. Kessler CM, Nussbaum E, Tuzaxon C. In vitro correlation of platelet aggregation with occurrence of disseminated intravascular coagulation and subacute bacterial endocarditis, J Lab Clin Med. 1987;109:9647–52.
12. Kupferwasser L, Yaman MR, Shapiro SM, Nast CC, Sullam PM, Filler SG, et al. Acetylsalicylic acid reduces vegetation bacterial density, hematogenous bacterial dissemination, and frequency of embolic events in experimental Staphylococcus aureus endocarditis through antplatelet and antibacterial effects. Circulation. 1999;99;2971–9.
13. Pepin J, Tremblay V, Bechard D, Rodier F, Walker C, Dufresne D, et al. Chronic antiplatelet therapy and mortality among patients with infective endocarditis. Clin Microbiol Infect. 2009;15:193–9.
14. Taha TH, Durrant SS, Mazeka PK, Nihoyannopoulos P, Oakley CM. Aspirin to prevent growth of vegetations and cerebral emboli in infective endocarditis. J Intern Med. 1992;231:543–6.
15. Eisen DP, Corey GR, McBryde ES, Fowler VJ, Miro JM, Cabell CH, et al. Acute thrombus and fibrinolysis in infective endocarditis. J Am Coll Cardiol. 2005;43:1134–5.
16. Connolly DL, Choudhury A, Davis RC, Lip GY. A randomized trial of aspirin on the risk of embolic events in patients with infective endocarditis. J Am Coll Cardiol. 2004;43:1134–5.